Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 40 of 41, showing 5 Applications out of 204 total, starting on record 196, ending on 200

# Protocol No Study Title Investigator(s) & Site(s)

196.

ECCT/13/04/09   Short-course RPT/INH for latent TB in HIV-infected individuals
        Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection   
Principal Investigator(s)
1. Deborah C. Langat
Site(s) in Kenya
1. Kenya Medical Research Institute Walter Reed Project Clinical Research Centre (Kericho county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

197.

ECCT/08/06/01   PARTNERS PrEP
    Parallel Comparison of Tenofovir and Emtricitabine/tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition within HIV-1 Discordant Couples   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. Kisumu site (Kisumu county)
 
View

198.

ECCT/13/04/04   Enteric Study
    A Randomized, Double-Blind, Clinical Trial Evaluating Three Single Dose Regimens with Loperamide for Treatment of Ambulatory Watery Travelers’ Diarrhea, and Azithromycin with and without Loperamide for Treatment of Ambulatory Dysentery/Febrile Diarrhea   
Principal Investigator(s)
1. CPT Brook A. Danboise
Site(s) in Kenya
British Army Training Unit, Kenya (BATUK)
 
View

199.

ECCT/12/04/02   Short-course RPT/INH for latent TB in HIV-infected individuals
    A5279: Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection       
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

200.

ECCT/08/27/12   MAL 55: A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection.
    Protocol No. 110021 - MAL 55 STUDY   A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa”   
Principal Investigator(s)
1. Dr. Mary Hamel
2. Dr. Patricia Njuguna
3. Dr. Walter Otieno
Site(s) in Kenya
1. KEMRI - CDC RESEARCH INSTITUTION CENTRE, KISUMU (Kisumu county)
2. KEMRI-WELLCOME TRUST RESEARCH CENTER, KILIFI SITE (Kilifi county)
3. KEMRI-WALTERREED, RESEARCH CENTRE, KOMBEWA SITE (Kisumu county)
 
View